Alseres Pharmaceuticals
Hopkinton
About Alseres Pharmaceuticals
Alseres Pharmaceuticals, Inc. (ALSE) is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system (CNS). Our lead product candidate is Altropane®, a proprietary molecular imaging agent used to diagnose Parkinson's disease and dementia. Altropane is presently in Phase III clinical development for the diagnosis of Parkinson's disease. Our development strategy for Altropane anticipates entering into one or more partnerships to ensure development and commercialization of the product.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $4.9M
- Funding stage: IPO
- Last round: Post-IPO Equity (Nov 2009)
- Ticker: otcpink:ALSE
- Website: alseres.com
- Phone: 508-497-2360
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/alseres-pharmaceuticals-1860803 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.